Bulletins - New medicine
Filter by category:AdministrationAdverse drug reactionsCannabis-based productsComplementary and Alternative Medicines (CAMs)Drug comparisonsExtremes of Age – paediatric and elderlyInteractionsNew medicineOtherPharmacokineticPregnancy/Breastfeeding
Vildagliptin for diabetes – funded in NZ - March 29, 2019
There are over 240,000 people in NZ currently diagnosed with diabetes mellitus (mostly type 2), and possibly another 100,000 undiagnosed. In October 2018, vildagliptin became the first dipeptidyl peptidase-4 (DPP-4) inhibitor funded in NZ. It is one of a number of DPP-4 inhibitors used internatio...